Sarepta Therapeutics (NASDAQ:SRPT) shares have gone supersonic! Up more than 800% year-to-date following today's 180% gains ahead of the closing bell, shares have broken the sound barrier (768 mph) on a percentage basis in 2012. The reason for today's elation is Sarepta's treatment for Duchenne muscular dystrophy, a drug called eteplirsen. 48-week trial data released this morning displayed incredible improvements for patients receiving a 50mg dose of the drug. In fact, the results showed some evidence that eteplirsen could help to reverse the progression of this fatal disease versus simply slowing its progression. While the news today is incredible for prospective patients and shareholders, the ultimate hurdle of approval from the Food and Drug Administration awaits. In the following video, Fool.com health care bureau chief Brenton Flynn runs through the news in more detail and offers a few words of caution for investors.
The Sarepta story is certainly one to pay attention to as it continues working on this revolutionary treatment for Duchenne. If you're looking for other revolutionary ideas, make sure to pick up a copy of the Fool's special free report titled: "The Next Trillion-Dollar Revolution." Inside the report, we not only describe a seismic shift that will dwarf any other technology revolution seen before it, but we also name a company at the forefront of the trend. Hundreds of thousands have requested access to previous reports, and you can access this new report today by clicking here -- it's free.
Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.